"dr-reddys-laboratories"

Pilot programme to administer from the first batch of 1,50,000 doses of Sputnik V vaccines imported from RDIF

Plan to vaccinate 125 million people in the next 8-12 months across the country

For FY21, the company posted a consolidated net profit of Rs 1,952 crore as against Rs 2,026 crore in 2019-20.

To manufacture and commercialise baricitinib in India, approved for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults

The latest therapy with links to the city is the glucose molecule 2-DG and its anti-Covid-19 therapeutic application that was given a green signal by Indian drug regulatory authorities

The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO).

Hyderabad-based Dr Reddy’s Laboratories has collaborated with RDIF to import the first consignment of Sputnik-V while it is expected that the pharma giant will start manufacturing from its local facilities in India

India has become the 60th country to approve Sputnik V, RDIF, Russia's sovereign wealth fund, said in a statement.

As part of the review process, the drug major will present the safety profile of phase 2 study, and interim data of phase 3 trial, which is expected to be complete by February 21

With a CGT designation, the company has a 180-day CGT exclusivity to market this product, he added.

Total revenue from operations stood at Rs 4,929.6 crore for the third quarter, up 12.38 per cent year-on-year

The trial will be conducted on 1,500 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in India

Exploring opportunities for mutual investments and trade in the life sciences sector

Trial will be a multicentre, randomised controlled study, which will include safety and immunogenicity

The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries.

Collaboration will allow Dr Reddy’s to identify and use some of the Biotechnology Industry Research Assistance Council’s clinical trial centres

Says it anticipates all services to be up within 24 hours and do not foresees any major impact on its operations

This will be a multi-centre and randomised controlled study, which will include safety and immunogenicity study, Dr Reddy’s said in a statement.

The company has committed to reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 55 per cent by 2030 from a FY2017-18 base year.